Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Nathan who wrote (9896)	6/2/1998 2:38:00 PM
From: Jenna	Respond to of 120523

RESEARCH ALERT-PhyCor <PHYC.O> upgraded to Strong BUY - J. Baker <JBAK.O> started as buy I've had JBAK on a watch list a while back.. The chart was really good at that time. It's still good with positive MACD, and positive relative strength. But the stock's volume indicators yesterdays showed it is coming under distribution. After today's upgrade, and price target, I think it will move up. I've traded PHYC before as well. Here we have the opposite situation. The chart was pretty dismal coming into today's trading. Nothing looked good, not one indicator was bullish, but a turnaround can be indicated after the STRONG BUY recommendation. Lots of times after a STRONG BUY, the stock shows a delayed reaction because traders are still hesitant, I would watch PHYC today/tomorrow to see a gain CHICAGO, June 2 (Reuters) - George K. Baum & Co. said Tuesday it upgraded PhyCor Inc. to strong buy from buy after talking with the company's management. Analyst Ken Laudan said in a statement the discussion with PhyCor management Monday confirmed his belief that the stock is undervalued. "Management's focus on reducing operating costs at acquired practices should lead to overall operating margin improvement of 15 to 20 basis points per year," Laudan said. "This, coupled with a more predictable acquisition backlog, argues for significant potential share price expansion." In afternoon action, shares of the Nashville, Tenn.-based physician practice management company were down 1/4 at 15-15/16. ********************************************************************** RESEARCH ALERT - J. Baker <JBAK.O> started as buy NEW YORK, June 2 (Reuters) - SBC Warburg Dillon Read said it initiated coverage of J. Baker Inc. with a buy rating and a 12-month target price of $22.50. -- After the company's 1997 divestitures it has emerged with a focused approach to its three neglected specialty businesses. -- At current valuations the stock was trading at a discount to its specialty-apparel peers. -- The earnings estimate for fiscal 1999 was set at $0.69 per share, and at $0.90 for the year 2000. -- J. Baker was up 1/8 at 12-3/4 in afternoon trading.